{
  "symbol": "EPIX",
  "company_name": "Essa Pharma",
  "ir_website": "https://essapharma.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with...",
          "url": "https://investors.essapharma.com/press-releases",
          "content": "  * Search: [](#)\n\n  * [](https://twitter.com/EssaPharma \"Tweet This\")\n  * [](https://www.linkedin.com/company/essa-pharmaceuticals \"Connect on LinkedIn\")\n\n\n\n![Essa Pharma](wp-content/uploads/bg-header-subpage-ir-home-min.jpg)\n\nPress Releases\n\n## Investors/Media\n\n  * [Investor Home](https://investors.essapharma.com/investor-home)\n  * [Press Releases](https://investors.essapharma.com/press-releases)\n  * [Financial Information](https://investors.essapharma.com/financial-information)\n  * [SEC Filings](https://investors.essapharma.com/sec-filings)\n  * [Corporate Governance](https://investors.essapharma.com/corporate-governance)\n  * [Committee Composition](https://investors.essapharma.com/committee-composition)\n  * [Stock Information](https://investors.essapharma.com/stock-information)\n  * [Analyst Coverage](https://investors.essapharma.com/analyst-coverage)\n  * [Events & Presentations](https://investors.essapharma.com/events-presentations)\n  * [Investor Contacts](https://investors.essapharma.com/investor-contacts)\n  * [Get News Alerts by Email](https://investors.essapharma.com/email-alerts)\n\n\n\nThese are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.\n\nSubscribe to Alerts\n\n* Required Fields \n\n* Email\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\n[ Get News Alerts by Email![](images/webdriver/email_alerts.png) ](https://investors.essapharma.com/email-alerts?type=1)\n\nYear All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Keywords Go\n\n[Advanced Search](#)\n\nSearch\n\nSearch Headlines Only\n\nFrom\n\nTo\n\nAsset Types\n\nPhotos Video Audio Documents Events Standard\n\n[Basic Search](#)\n\n  * Oct 31, 2024\n\n[ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer](https://investors.essapharma.com/2024-10-31-ESSA-Pharma-Announces-Termination-of-Phase-2-Study-Evaluating-Masofaniten-Combined-with-Enzalutamide-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer)\n\nEfficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility...\n\n  * Sep 13, 2024\n\n[ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress](https://investors.essapharma.com/2024-09-13-ESSA-Pharma-Presents-Updated-Phase-1-2-Masofaniten-EPI-7386-Clinical-Data-at-the-2024-ESMO-Congress)\n\nCombination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of...\n\n  * Sep 11, 2024\n\n[ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference](https://investors.essapharma.com/2024-09-11-ESSA-Pharma-to-Present-at-the-2024-Cantor-Global-Healthcare-Conference)\n\nESSA Pharma Inc. (\"ESSA,\" or the \"Company\") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the...\n\n  * Aug 5, 2024\n\n[ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024](https://investors.essapharma.com/2024-08-05-ESSA-Pharma-Provides-Corporate-Update-and-Reports-Financial-Results-for-Fiscal-Third-Quarter-Ended-June-30,-2024)\n\nOn track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase\n\n  * Jul 8, 2024\n\n[ESSA Pharma to Present at the JonesHealthcare Seaside Summit](https://investors.essapharma.com/2024-07-08-ESSA-Pharma-to-Present-at-the-JonesHealthcare-Seaside-Summit)\n\nESSA Pharma Inc. (\"ESSA,\" or the \"Company\") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that...\n\n\n\n\nShow \n\n5\n\nper page\n\n[](#top \"Back to Top\")\n\n##### Corporate Presentation\n\n![Corporate Presentation](wp-content/uploads/img-corporate-presentation-min.jpg)\n\nClose\n\n[5](https://investors.essapharma.com/press-releases?l=5)[10](https://investors.essapharma.com/press-releases?l=10)[25](https://investors.essapharma.com/press-releases?l=25)[50](https://investors.essapharma.com/press-releases?l=50)[100](https://investors.essapharma.com/press-releases?l=100)\n"
        },
        {
          "title": "ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024...",
          "url": "https://investors.essapharma.com/press-releases",
          "content": "  * Search: [](#)\n\n  * [](https://twitter.com/EssaPharma \"Tweet This\")\n  * [](https://www.linkedin.com/company/essa-pharmaceuticals \"Connect on LinkedIn\")\n\n\n\n![Essa Pharma](wp-content/uploads/bg-header-subpage-ir-home-min.jpg)\n\nPress Releases\n\n## Investors/Media\n\n  * [Investor Home](https://investors.essapharma.com/investor-home)\n  * [Press Releases](https://investors.essapharma.com/press-releases)\n  * [Financial Information](https://investors.essapharma.com/financial-information)\n  * [SEC Filings](https://investors.essapharma.com/sec-filings)\n  * [Corporate Governance](https://investors.essapharma.com/corporate-governance)\n  * [Committee Composition](https://investors.essapharma.com/committee-composition)\n  * [Stock Information](https://investors.essapharma.com/stock-information)\n  * [Analyst Coverage](https://investors.essapharma.com/analyst-coverage)\n  * [Events & Presentations](https://investors.essapharma.com/events-presentations)\n  * [Investor Contacts](https://investors.essapharma.com/investor-contacts)\n  * [Get News Alerts by Email](https://investors.essapharma.com/email-alerts)\n\n\n\nThese are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.\n\nSubscribe to Alerts\n\n* Required Fields \n\n* Email\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\n[ Get News Alerts by Email![](images/webdriver/email_alerts.png) ](https://investors.essapharma.com/email-alerts?type=1)\n\nYear All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Keywords Go\n\n[Advanced Search](#)\n\nSearch\n\nSearch Headlines Only\n\nFrom\n\nTo\n\nAsset Types\n\nPhotos Video Audio Documents Events Standard\n\n[Basic Search](#)\n\n  * Oct 31, 2024\n\n[ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer](https://investors.essapharma.com/2024-10-31-ESSA-Pharma-Announces-Termination-of-Phase-2-Study-Evaluating-Masofaniten-Combined-with-Enzalutamide-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer)\n\nEfficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility...\n\n  * Sep 13, 2024\n\n[ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress](https://investors.essapharma.com/2024-09-13-ESSA-Pharma-Presents-Updated-Phase-1-2-Masofaniten-EPI-7386-Clinical-Data-at-the-2024-ESMO-Congress)\n\nCombination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of...\n\n  * Sep 11, 2024\n\n[ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference](https://investors.essapharma.com/2024-09-11-ESSA-Pharma-to-Present-at-the-2024-Cantor-Global-Healthcare-Conference)\n\nESSA Pharma Inc. (\"ESSA,\" or the \"Company\") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the...\n\n  * Aug 5, 2024\n\n[ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024](https://investors.essapharma.com/2024-08-05-ESSA-Pharma-Provides-Corporate-Update-and-Reports-Financial-Results-for-Fiscal-Third-Quarter-Ended-June-30,-2024)\n\nOn track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase\n\n  * Jul 8, 2024\n\n[ESSA Pharma to Present at the JonesHealthcare Seaside Summit](https://investors.essapharma.com/2024-07-08-ESSA-Pharma-to-Present-at-the-JonesHealthcare-Seaside-Summit)\n\nESSA Pharma Inc. (\"ESSA,\" or the \"Company\") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that...\n\n\n\n\nShow \n\n5\n\nper page\n\n[](#top \"Back to Top\")\n\n##### Corporate Presentation\n\n![Corporate Presentation](wp-content/uploads/img-corporate-presentation-min.jpg)\n\nClose\n\n[5](https://investors.essapharma.com/press-releases?l=5)[10](https://investors.essapharma.com/press-releases?l=10)[25](https://investors.essapharma.com/press-releases?l=25)[50](https://investors.essapharma.com/press-releases?l=50)[100](https://investors.essapharma.com/press-releases?l=100)\n"
        },
        {
          "title": "ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference",
          "url": "https://investors.essapharma.com/press-releases",
          "content": "  * Search: [](#)\n\n  * [](https://twitter.com/EssaPharma \"Tweet This\")\n  * [](https://www.linkedin.com/company/essa-pharmaceuticals \"Connect on LinkedIn\")\n\n\n\n![Essa Pharma](wp-content/uploads/bg-header-subpage-ir-home-min.jpg)\n\nPress Releases\n\n## Investors/Media\n\n  * [Investor Home](https://investors.essapharma.com/investor-home)\n  * [Press Releases](https://investors.essapharma.com/press-releases)\n  * [Financial Information](https://investors.essapharma.com/financial-information)\n  * [SEC Filings](https://investors.essapharma.com/sec-filings)\n  * [Corporate Governance](https://investors.essapharma.com/corporate-governance)\n  * [Committee Composition](https://investors.essapharma.com/committee-composition)\n  * [Stock Information](https://investors.essapharma.com/stock-information)\n  * [Analyst Coverage](https://investors.essapharma.com/analyst-coverage)\n  * [Events & Presentations](https://investors.essapharma.com/events-presentations)\n  * [Investor Contacts](https://investors.essapharma.com/investor-contacts)\n  * [Get News Alerts by Email](https://investors.essapharma.com/email-alerts)\n\n\n\nThese are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.\n\nSubscribe to Alerts\n\n* Required Fields \n\n* Email\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\n[ Get News Alerts by Email![](images/webdriver/email_alerts.png) ](https://investors.essapharma.com/email-alerts?type=1)\n\nYear All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Keywords Go\n\n[Advanced Search](#)\n\nSearch\n\nSearch Headlines Only\n\nFrom\n\nTo\n\nAsset Types\n\nPhotos Video Audio Documents Events Standard\n\n[Basic Search](#)\n\n  * Oct 31, 2024\n\n[ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer](https://investors.essapharma.com/2024-10-31-ESSA-Pharma-Announces-Termination-of-Phase-2-Study-Evaluating-Masofaniten-Combined-with-Enzalutamide-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer)\n\nEfficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility...\n\n  * Sep 13, 2024\n\n[ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress](https://investors.essapharma.com/2024-09-13-ESSA-Pharma-Presents-Updated-Phase-1-2-Masofaniten-EPI-7386-Clinical-Data-at-the-2024-ESMO-Congress)\n\nCombination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of...\n\n  * Sep 11, 2024\n\n[ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference](https://investors.essapharma.com/2024-09-11-ESSA-Pharma-to-Present-at-the-2024-Cantor-Global-Healthcare-Conference)\n\nESSA Pharma Inc. (\"ESSA,\" or the \"Company\") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the...\n\n  * Aug 5, 2024\n\n[ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024](https://investors.essapharma.com/2024-08-05-ESSA-Pharma-Provides-Corporate-Update-and-Reports-Financial-Results-for-Fiscal-Third-Quarter-Ended-June-30,-2024)\n\nOn track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase\n\n  * Jul 8, 2024\n\n[ESSA Pharma to Present at the JonesHealthcare Seaside Summit](https://investors.essapharma.com/2024-07-08-ESSA-Pharma-to-Present-at-the-JonesHealthcare-Seaside-Summit)\n\nESSA Pharma Inc. (\"ESSA,\" or the \"Company\") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that...\n\n\n\n\nShow \n\n5\n\nper page\n\n[](#top \"Back to Top\")\n\n##### Corporate Presentation\n\n![Corporate Presentation](wp-content/uploads/img-corporate-presentation-min.jpg)\n\nClose\n\n[5](https://investors.essapharma.com/press-releases?l=5)[10](https://investors.essapharma.com/press-releases?l=10)[25](https://investors.essapharma.com/press-releases?l=25)[50](https://investors.essapharma.com/press-releases?l=50)[100](https://investors.essapharma.com/press-releases?l=100)\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "View Latest Corporate Presentation",
          "url": "https://essapharma.com/wp-content/uploads/ESSA_Corporate-Presentation_August-2023.pdf",
          "content": "CORPORATE PRESENTATION\nAugust 2023\nX\nI\nP\nE\n:\nQ\nA\nD\nS\nA\nN\nForward Looking Statements\nCertainwrittenstatementsinand/ororalstatementsmadeinconnectionwiththispresentationmaybeconsideredforward-lookingstatementswithinthemeaningof\napplicableCanadiansecuritieslawsandtheUnitedStatessecuritieslaws,thatmaynot bebasedonhistoricalfact,including,withoutlimitation,statementscontaining\nthe words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “predict”, “project”, “intend”, “expect”, “potential” and similar expressions. Forward-\nlookingstatementsinthispresentationinclude,butarenotlimitedto:themortalityrateofprostatecancer;ESSA’supcomingmilestones; potentialtreatmentsforEPI-\n7386; EPI-7386’s Phase1studyanditssuccess;clinicaltrials;andpotentialmarketopportunitiesforEPI-73896.\nForward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to\ncontrol or predict, and which may cause ESSA’s actual results, performance or achievements tobe materially different from those expressed or implied thereby. Such\nstatementsreflectESSA’scurrentviewswithrespecttofutureevents,aresubjecttorisksanduncertaintiesandarenecessarilybaseduponanumberofestimatesand\nassumptionsthat,whileconsideredreasonablebyESSAas of thedateof suchstatements,areinherentlysubjecttosignificantmedical,scientific,business,economic,\ncompetitive, political and social uncertainties and contingencies, many of which, with respect to future events, are subject to change. In making forward-looking\nstatements,ESSAmaymakevariousmaterialassumptions,includingbutnotlimitedtothemarketanddemandforthesecuritiesofESSA,generalbusiness,marketand\neconomicconditions,obtainingpositiveresultsofclinicaltrials,andobtainingregulatoryapprovals.\nForward-lookinginformationisdevelopedbasedonassumptionsaboutsuch risks,uncertaintiesandotherfactorssetout hereinandinESSA’sAnnualReporton Form\n10-K filed on December 13, 2022 under the heading “Risk Factors”, a copy of which is available on ESSA’s profile on the SEDAR website at www.sedar.com, ESSA’s\nprofile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA’s SEDAR profile and EDGAR profile. Forward-looking statements are made\nbased on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking\nstatements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable Canadian and United States\nsecurities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and investors are cautioned not to put undue\nrelianceonforward-lookingstatementsduetotheirinherentuncertainty.\n2\nESSA Corporate Overview\nCompany\n• Experienced management team with deep expertise in oncology and drug development\n• Headquartered in South San Francisco and Vancouver\nFocused on the\nTechnology & Products\ndevelopment of novel\ntherapies for the • Lead candidate EPI-7386is a first-in-class oral, small molecule androgen receptor N-\nterminal domain inhibitor (“Aniten”)\ntreatment of prostate\n• EPI-7386 is being developed as a monotherapy in late-stage metastatic castration-\nresistant prostate cancer (“PC”) and in antiandrogen combinations in earlier stage PC\nand other androgen-\n• Initial clinical data show EPI-7386 is well-tolerated as a monotherapy and in combination\nwith leading antiandrogens; early combination data with enzalutamide showed 4/6\ndriven cancers\npatients achieving a PSA90 in 90 days\n• First generation AR NTD protein degrader (ANITAC) in preclinical development\nFinancial Details\n• Listed on NASDAQ (EPIX)\n• Cash and short-term deposits: $157M (March 31, 2023); runway through 2025\n3\nExperienced Management Team\nDavid R. Parkinson, MD Peter Virsik, MS, MBA\nPresident & Chief Executive Officer EVP & Chief Operating Officer\nDavid S. Wood, MBA, CPA, CMA Alessandra Cesano, MD\nChief Financial Officer EVP & Chief Medical Officer\n4\nProstate Cancer Disease Landscape\nNEED FOR NEW\nPUBLIC HEALTH LARGE VALIDATED\nTHERAPEUTIC\nPROBLEM MARKET THERAPEUTIC TARGET\nSTRATEGIES\n• Prostate cancer is the 2nd • Over $9B in global sales • Androgen receptor (AR) • Resistance to second-\nmost common cause of generated in 2022 by signaling is critical for prostate generation antiandrogens is\nmale cancer deaths leading antiandrogens2 cancer development and common and on average\nprogression3,4,5 occurs within a year of\n• Newest antiandrogens:\n• American Cancer Society starting therapy6\nZytiga® (abiraterone • Mounting evidence that\nestimates 268,000 new\nacetate), Xtandi® progression to CRPC remains • Clinical results suggest that\ncases and 34,500 deaths in\n(enzalutamide), Erleada® dependent upon persistent more potent AR inhibition\n20221\n(apalutamide) and Nubeqa® AR signaling driven by AR used earlier in therapy may\n(darolutamide)2 resistance mechanisms3,5 provide improved clinical\noutcomes for patients7\n1. American Cancer Society. (2022). Key Statistics for Prostate Cancer. Retrieved from 3. Robinson D, et al. Cell, 2015. 6. Sharp A, et al. JCI, 2019.\nhttps://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. 4. Chen CD, et al. Nat Med, 2004. 7. ESMO2021.\n5\n2. 2022 financial reports from www.sec.gov. 5. Kumar A, et al. Nat Med, 2016.\nProstate Cancer Evolution and AR Dependency\nLocal Systemic\nmCSPC\nProstate Clinically mCRPC mCRPC mCRPC\nRising PSA\nCancer1 Localized\nNoncastrate 1st Line 2nd Line 3rd+ Line\nDisease\nnmCRPC\nAR Genomic Structural Rearrangements and Splice Variants\nAR Truncations and Splice Variants\nAR Amplification\nAR LBD Point Mutations\nAR Dependent\nAR Independent\nPTEN-PI3K-AKT, Wnt, neuroendocrine, other tumor growth drivers\n1. Adopted from Scher, HI, et al. J Clin Oncol, 2016. 6\nEPI-7386, First-in-Class NTD AR\nInhibitor\nEPI-7386’s Novel MoA Uniquely Inhibits the NTD of the Androgen\nReceptor, Potentially Overcoming Resistance to Standard-of-Care\n• All current antiandrogens function through the ligand-\nbinding domain (LBD) of the androgen receptor (AR)\n• Known antiandrogen resistance mechanisms\ndevelop at the LBD\n• EPI-7386 specifically binds to the N-terminal domain\n(NTD) of the AR, a region of the androgen receptor\nrequired for AR activity\n• As a result of this binding, EPI-7386 is active against\nmultiple AR forms, including those resistant to current\nantiandrogens\n• EPI-7386’s novel method of inhibiting the AR may lead\nto greater AR suppression when used in combination\nwith current antiandrogen therapies\nN-terminal domain DNA-binding domain Ligand-binding domain\nGranted unique USAN drug stem of “Aniten” as a AR NTD inhibitor\n1. Hong NH, et al. AACR-NCI-EORTC-Virtual Int Conf, 2021. 3. Andersen RJ, et al. Cancer Cell, 2010. 5. Yang YC, et al. Clin Cancer Res, 2016.\n2. De Mol E, et al. ACS Chem Biol, 2016. 4. De Mol E, et al. ACS Chem Biol, 2016. 8\nEPI-7386 Monotherapy Clinical Development for AR-Driven CRPC\nLocal Systemic\nmCSPC\nProstate Clinically mCRPC mCRPC mCRPC\nRising PSA\nCancer1 Localized\nNoncastrate 1st Line 2nd Line 3rd+ Line\nDisease\nnmCRPC\nAR Genomic Structural Rearrangements and Splice Variants\nAR Amplification\nAR LBD Point Mutations\nAR Dependent\nAR Independent\nPTEN-PI3K-AKT, Wnt, neuroendocrine, other tumor growth drivers\nEPI-7386\nCurrent EPI-7386\nDevelopment Monotherapy\n1. Adopted from ScherHI, et al. J Clin Oncol, 2016. 9\nEPI-7386 Phase 1 Monotherapy Study in mCRPC Patients: Study\nDesign\n• First-in-human Phase 1 multi-center open-label study enrolling mCRPC patients failing standard-of-care therapy\n• Two-part study: Phase 1a dose-escalation (Completed) followed by Phase 1b dose expansion (Currently enrolling)\nPhase 1a: QD Dosing Regimen Phase 1a: BID Dosing Regimen\nOriginal Protocol Amended Protocol\nN = 31 patients N = 8 patients\nQD dosing 1000 mg BID dosing\n800 mg\n600 mg BID\n600 mg\n(1200 mg/day)\n400 mg\n1200 mg\n400 mg BID\n200 mg\n(800 mg/day)\n)\n• No limitations on the # prior lines of therapy • Limited to ≤ 3 prior lines of therapy\n• Visceral metastases permitted • Exclusion of visceral metastases\n• Prior chemotherapy permitted • One lineof prior chemotherapy permitted\n10\nEPI-7386 Monotherapy Phase 1a: Key Findings\nKey safety results and pharmacokinetic data from both QD and BID patients as of June 1, 2022:\n• EPI-7386 was safe and well-tolerated at all dose levels and schedules tested, with no dose-limiting toxicities and only\nGrade 1 and Grade 2 adverse events\n• EPI-7386 has a long half life (>24hrs) and steady state AUC EPI-7386 exposures increase with higher doses; all doses\nreached exposures above the minimum target drug threshold\nKey response findings in both QD and BID patients as of June 1, 2022:\n• Tumor volume decreased in five patients who had measurable disease and were on therapy for more than 12 weeks\n• In 17 patients with measurable ctDNA levels at baseline, ctDNA declines were observed in patients harboring AR\npoint mutations, AR gain/amplification and AR truncations, suggesting EPI-7386's activity against these tumors\n• PSA decreased or PSA stabilized in a clinical subset of patients: no visceral disease, fewer DNA genomic aberrations in\nnon-AR oncogenic pathways, and fewer than 3 lines of therapy\n• Provides further information to refine the monotherapy development program patient population\n11\nNext Steps in the EPI-7386 Phase 1 Monotherapy Study\n• Verify the recommended Phase 2 dose – 600mg BID or 600 mg QD\n• Understand late stage mCRPC patient biology and identify patients with AR-driven tumors\n• Gain further insight of the biological activity of EPI-7386 in less heavily pretreated patients\nPhase 1b dose(s)/schedule(s) recommendation\nPhase 1b: Dose Expansion Phase 1b: Window of Opportunity\n600mg BID 600mg QD 600mg BID\n• mCRPC: • Non-metastatic CRPC (nmCRPC) patients\n- ≤ 3 prior lines of therapy, no visceral disease, no • 600mg BID Cohort\nprior chemotherapy • 12 weeks of EPI-7386 monotherapy treatment before\n• 2 Cohorts: QD & BID dosing combining with apalutamide\n• Molecular tumor characterization\n12\nEPI-7386 in Combination with Second\nGeneration Antiandrogens\nEPI-7386 Combination Study Clinical Program for AR-Driven CRPC\nLocal Systemic\nmCSPC\nProstate Clinically mCRPC mCRPC mCRPC\nRising PSA\nCancer1 Localized\nNoncastrate 1st Line 2nd Line 3rd+ Line\nDisease\nnmCRPC\nAR Genomic Structural Rearrangements and Splice Variants\nAR Amplification\nAR LBD Point Mutations\nAR Dependent\nAR Independent\nPTEN-PI3K-AKT, Wnt, neuroendocrine, other tumor growth drivers\nEPI-7386 Current EPI-7386 + Antiandrogen\nDevelopment Combinations\n1. Adopted from Scher, HI, et al. J Clin Oncol, 2016. 14\nPreclinical Rationale for the Combination of EPI-7386 with Antiandrogens\nAR Binding to Genomic DNA Mouse VCaP Xenograft Efficacy\n• Decades of clinical research link\nimproved clinical results with deeper\nAR axis suppression\nVehicle\n• Combining an AR NTD-inhibitor with\nENZ\nan LBD-inhibitor provides two\nEPI-7386\nENZ+ complementary ways of inhibiting AR\nEPI-7386\nbiology\n• Preclinical studies support deeper\nand broader suppression of AR-\ndriven biology by combining EPI-7386\nwith antiandrogens\n15\nEPI-7386 Combination Development Program with Second-\nGeneration Antiandrogens\nESSA collaboration with Astellas to evaluate EPI-7386 in combination with Xtandi®\n(enzalutamide) in an ESSA-sponsored Phase 1/2 clinical study in mCRPC patients naïve\nto second generation antiandrogens (study began 1Q2022)\nESSA collaboration with Janssen to evaluate EPI-7386 in combination with Erleada ®\n(apalutamide) and Zytiga ® (abiraterone acetate) + prednisone in Phase 1 clinical study\ncohorts evaluating apalutamide + EPI-7386 in nmCRPC patients and also abiraterone and\nprednisone in combination with EPI-7386 in mCRPC patients naïve to second generation\nantiandrogens and in mCSPC patients.\nBayer collaboration with ESSA to evaluate EPI-7386 in combination with Nubeqa ®\n(darolutamide) in a Phase 1/2 clinical study in mCRPC patients\nInvestigator-\nA 12-week two-arm randomized study of Nubeqa vs. EPI-7386 + Nubeqa in PC patients\nSponsored\nundergoing prostatectomy for high risk localized prostatecancer\nNeoadjuvant Study\n16\nPhase 1/2 EPI-7386 + Enzalutamide (ENZ) Combination Study Trial\nDesign in mCRPC Patients Naïve to Second-Generation Antiandrogens\n• Phase 1/2 multi-center open-label study enrolling mCRPC patients naïve to second-generation antiandrogens\n• Two-part study: Phase 1 dose-equilibration followed by Phase 2 open-label randomized study\nPhase 1: QD Dosing Equilibration Phase 2: Head-to-Head Comparison\nEnrolling\nN = ~18 patients\nDose 4 EPI-7386\nDLT period\n160 mg ENZ\nOptimal combination\ncompleted N = 80 patients\ndoses from Phase 1a\nDose 3 EPI-7386\nDLT period Dose 4\n120 mg ENZ\ncompleted\nvs.\n800 mg EPI-7386\nDLT period\ncompleted 120 mg ENZ\n160 mg ENZ N = 40 patients\n600 mg EPI-7386\n120 mg ENZ\n• Phase 1 study will focus on the PK and safety of EPI-7386 and enzalutamide when administered in combination along with\nestablishing the RP2D for both drugs to address any possible drug-drug interactions\n• Phase 2 study will assess the anti-tumor activity of the combination of EPI-7386 and enzalutamide versus single agent\nenzalutamide at the standard of care dose\n17\nInitial Data from First Two Cohorts in Phase 1/2 EPI-7386 + ENZ\nCombination Study\n• EPI-7386 and ENZ were well-tolerated with no DLTs, no Grade 3 drug-related\nSafety\nAEs, and a safety profile consistent with second generation antiandrogens (e.g.\ngrade 1 or 2 AEs of fatigue and hot-flashes)\n• ENZ exposure minimally impacted by EPI-7386 administration\n• EPI-7386 exposure impacted by ENZ with lower exposures of EPI-7386\nPharmacokinetics observed, as anticipated; 4 dose cohorts will be needed to determine the\n(PK) combination RP2D\n• One patient was discontinued from the study after the DLT period due to a\nconcomitant medication (strong CYP3A inducer) interaction with ENZ and EPI-\n7386 which resulted in a significant decrease in exposure to both drugs\n18\n*Treatment Related Adverse Event (TRAE)\nLongitudinal PSA Changes Under EPI-7386 + ENZ Treatment from the\nFirst Two Cohorts of Patients\nClinical Activity\n• Rapid, deep and durable PSA\nreductions observed\n• 5 of 6 patients achieved a\nPSA90 regardless of prior\nchemotherapy status\n• 4 of 6 patients achieved a\nPSA90 in 90 days and\nultimately achieved a PSA <\n0.2ng/mL\n• Cohort 3 DLT period is\ncompleted and patients are\nbeing enrolled into Cohort 4\n19\nPSA Data from Second Generation Antiandrogen Studies (2012-2021)\nPivotal second generation antiandrogen studies show deep early PSA declines\nmCRPC Patient Agent PSA90 Study Type PSA90 PSA <0.2 Reference\nPopulation (90 Days) (Overall) ng/mL\n(Overall)\nPre-Chemo Setting\nPREVAIL Study ENZ 37% Pivotal 47% 12%+ Beers et al., NEJM, 2014; Armstrong et al., Eu Assoc\nof Uro, 2020; Armstong, et al. Eu UrolOnc_2019\nPREMISE Study ENZ - - Observational 45% - - Payne et al., Int J of Canc, 2021.\nACIS Study ABI - - Pivotal 47% 19% Saad et al., Lancet Onc, 2021.\nACIS Study ABI+APA - - Pivotal 53% 25% Saad et al., Lancet Onc, 2021.\nPost-Chemo Setting\nAFFIRM Study ENZ 13% Pivotal 25% - - Scheret al., NEJM, 2012; Armstrong et al., Cancer\n2017.\nPREMISE Study ENZ - - Observational 31% - - Payne et al., Int J of Canc, 2021.\nEarly EPI-7386 + ENZ combination PSA90 data compare favorably to pivotal ENZ and other antiandrogen\nstudies, suggesting potential long-term clinical benefit of combination treatment*\n* Armstong, et al. Eu UrolOnc_2019.; +Estimate derived from Armstong, et al. Eu UrolOnc_2019\n20\nIn Prior Studies of ENZ in CRPC Patients, Deep PSA Declines\nwere Associated with Better Long-Term Overall Survival*\nFrom the PREVAIL study of mCRPC patients, the From the PROSPER study of nmCRPC patients,\ndeeper the PSA decline during the initial 13-week the deeper the 12-month PSA nadir, the\nperiod, the better the long-term overall survival better the long-term overall survival\n* Armstong, et al. Eu Urol_2020; Hussain, et al. The J of Uro_2023.\n21\nMilestones and Cash Flow\nESSA Research and Development Pipeline\nEPI-7386\nPROGRAM INDICATION RESEARCH PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COLLABORATIONS\nmCRPC –Resistant to\nstandard of care\nEPI-7386 monotherapy treatments\nNon-PC AR-driven Cancers\nEPI-7386 + enzalutamide mCRPC\nEPI-7386 + abiraterone\nmCRPC+ mCSPC\nacetate + prednisone\nEPI-7386 + apalutamide nmCRPC\nEPI-7386 + darolutamide mCRPC\nDiscovery\nPROGRAM INDICATION RESEARCH PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COLLABORATIONS\n3rd-Generation\nAR N-Terminal Domain Prostate Cancer\nInhibitor\nAR N-Terminal Domain\nProstate Cancer\nDegrader (“ANITAC”)\nAR N-Terminal\nProstate Cancer\nDomain Tau-1 Site Inhibitor\n23\nESSA Upcoming Milestones\nEPI-7386 Programs Timing\nMonotherapy\nPresent clinical update on Phase 1 trial Completed\nEstablish the recommended Phase 2 dose (RP2D) Completed\nInitiate Phase 1b expansion study Completed\nComplete enrollment into the Phase 1b expansion study 2023\nCombination\nComplete Phase 1 EPI-7386/enzalutamide combination study 3Q 2023\nEstablish the RP2D for EPI-7386/enzalutamide combination trial 3Q 2023\nInitiate Phase 2 portion of EPI-7386/enzalutamide combination trial 3Q2023\nEnrollment of apalutamide and abiraterone acetate cohorts 2H2023\nDiscovery Timing\nInitiate IND-enabling studies for an ANITAC NTD degrader or an Aniten 2023\n24\nFinancial Position & Capitalization\nNasdaq: EPIX\nCash $152.5M reported at August 8, 2023 (no debt O/S)\nShares ~47M (44M I/O common shares and 3M prefunded warrants)\nCovering Analysts Bloom Burton - David Martin | Jefferies - Maury Raycroft\nOppenheimer – Leland Gershell| Piper Sandler - Joe Catanzaro\nCurrent cash runway through 2025 funds:\n• Completion of Phase 1 dose escalation & expansion monotherapy studies\n• Completion of Phase 1/2 combination studies with antiandrogens\n• Phase 2 monotherapy pivotal study\n• Phase 2 combination study with enzalutamide and Phase 1 combination study with abiraterone and apalutamide\n• Pipeline work including preclinical studies with Anitens in other AR-driven tumors\n25\nFor further information, please contact:\nPeter Virsik, Chief Operating Officer\npvirsik@essapharma.com"
        }
      ]
    }
  ]
}